Simtuzumab
Simtuzumab is an experimental drug that was under development by Gilead Sciences for the treatment of Idiopathic pulmonary fibrosis and Liver fibrosis. It is a monoclonal antibody that targets LOXL2, an enzyme that cross-links collagen and elastin in the extracellular matrix.
History[edit]
Simtuzumab was originally developed by Arresto Biosciences, which was acquired by Gilead Sciences in 2011. The drug entered Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis and liver fibrosis in 2012. However, the trials were discontinued in 2016 due to lack of efficacy.
Mechanism of Action[edit]
Simtuzumab works by binding to LOXL2, an enzyme that is involved in the cross-linking of collagen and elastin in the extracellular matrix. By inhibiting this enzyme, the drug is thought to reduce fibrosis.
Clinical Trials[edit]
Simtuzumab has been tested in several clinical trials for the treatment of various fibrotic diseases. However, the results have been disappointing. In 2016, Gilead Sciences announced that it was discontinuing the development of the drug due to lack of efficacy in Phase 2 trials.
Future Development[edit]
Despite the disappointing results, research into the role of LOXL2 in fibrosis continues. It is hoped that future drugs targeting this enzyme will be more effective.
See Also[edit]
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page. |
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
